← brief for 2026-09-10 · Slowing decline

Effect of Empagliflozin in Patients With eGFR Between 10 and 20 ml/Min/1.73m2

Trial No results yet Not peer reviewed

Key takeaways

This trial tests empagliflozin, a diabetes drug that also protects kidneys, in people whose kidneys are barely working. Their kidney filtering rate (eGFR) is between 10 and 20, which is close to needing dialysis. Researchers think the drug can still flush out salt at this stage and cut protein in the urine, which might protect what kidney function is left. The study is starting, so there are no results yet.

Who did this work

Run by Centre Hospitalier Universitaire de Nice. Guillaume FAVRE, MD-PHD (Centre Hospitalier Universitaire de Nice)
Sites: CHU Nice - Hôpital Pasteur 2

Source

Trial · ClinicalTrials.gov, CKD recruiting · 2026-09-10
https://clinicaltrials.gov/study/NCT07074418